Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors.

Jahchan NS, Dudley JT, Mazur PK, Flores N, Yang D, Palmerton A, Zmoos AF, Vaka D, Tran KQ, Zhou M, Krasinska K, Riess JW, Neal JW, Khatri P, Park KS, Butte AJ, Sage J.

Cancer Discov. 2013 Dec;3(12):1364-77. doi: 10.1158/2159-8290.CD-13-0183. Epub 2013 Sep 26.

2.

Teaching an old dog new tricks: drug repositioning in small cell lung cancer.

Wang J, Byers LA.

Cancer Discov. 2013 Dec;3(12):1333-5. doi: 10.1158/2159-8290.CD-13-0790.

3.

Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells.

Pettersson HM, Pietras A, Munksgaard Persson M, Karlsson J, Johansson L, Shoshan MC, Påhlman S.

Mol Cancer Ther. 2009 Jan;8(1):160-70. doi: 10.1158/1535-7163.MCT-08-0595.

4.

Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.

Faber AC, Farago AF, Costa C, Dastur A, Gomez-Caraballo M, Robbins R, Wagner BL, Rideout WM 3rd, Jakubik CT, Ham J, Edelman EJ, Ebi H, Yeo AT, Hata AN, Song Y, Patel NU, March RJ, Tam AT, Milano RJ, Boisvert JL, Hicks MA, Elmiligy S, Malstrom SE, Rivera MN, Harada H, Windle BE, Ramaswamy S, Benes CH, Jacks T, Engelman JA.

Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1288-96. doi: 10.1073/pnas.1411848112. Epub 2015 Mar 3.

5.

Chemotherapy-Regulated microRNA-125-HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer.

Yagishita S, Fujita Y, Kitazono S, Ko R, Nakadate Y, Sawada T, Kitamura Y, Shimoyama T, Maeda Y, Takahashi F, Takahashi K, Tamura T, Koizumi F.

Mol Cancer Ther. 2015 Jun;14(6):1414-23. doi: 10.1158/1535-7163.MCT-14-0625. Epub 2015 Apr 1.

6.
7.

Selective M3 muscarinic receptor antagonist inhibits small-cell lung carcinoma growth in a mouse orthotopic xenograft model.

Ami N, Koga K, Fushiki H, Ueno Y, Ogino Y, Ohta H.

J Pharmacol Sci. 2011;116(1):81-8. Epub 2011 Apr 21.

8.

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.

Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, Desai R, Escarpe PA, Hampl J, Laysang A, Liu D, Lopez-Molina J, Milton M, Park A, Pysz MA, Shao H, Slingerland B, Torgov M, Williams SA, Foord O, Howard P, Jassem J, Badzio A, Czapiewski P, Harpole DH, Dowlati A, Massion PP, Travis WD, Pietanza MC, Poirier JT, Rudin CM, Stull RA, Dylla SJ.

Sci Transl Med. 2015 Aug 26;7(302):302ra136. doi: 10.1126/scitranslmed.aac9459.

9.

Evaluation of novel orthotopic nude mouse models for human small-cell lung cancer.

Isobe T, Onn A, Morgensztern D, Jacoby JJ, Wu W, Shintani T, Itasaka S, Shibuya K, Koo PJ, O'Reilly MS, Herbst RS.

J Thorac Oncol. 2013 Feb;8(2):140-6. doi: 10.1097/JTO.0b013e3182725ff9.

10.

The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo.

Pardo OE, Latigo J, Jeffery RE, Nye E, Poulsom R, Spencer-Dene B, Lemoine NR, Stamp GW, Aboagye EO, Seckl MJ.

Cancer Res. 2009 Nov 15;69(22):8645-51. doi: 10.1158/0008-5472.CAN-09-1576. Epub 2009 Nov 10.

11.

Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.

Baker AF, Hanke NT, Sands BJ, Carbajal L, Anderl JL, Garland LL.

J Exp Clin Cancer Res. 2014 Dec 31;33:111. doi: 10.1186/s13046-014-0111-8.

12.

Combination of arsenic trioxide and chemotherapy in small cell lung cancer.

Zheng CY, Lam SK, Li YY, Fong BM, Mak JC, Ho JC.

Lung Cancer. 2013 Nov;82(2):222-30. doi: 10.1016/j.lungcan.2013.08.022. Epub 2013 Sep 3.

PMID:
24041618
13.

Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer.

Cañadas I, Rojo F, Taus Á, Arpí O, Arumí-Uría M, Pijuan L, Menéndez S, Zazo S, Dómine M, Salido M, Mojal S, García de Herreros A, Rovira A, Albanell J, Arriola E.

Clin Cancer Res. 2014 Feb 15;20(4):938-50. doi: 10.1158/1078-0432.CCR-13-1330. Epub 2013 Nov 27.

14.

Loss of YAP1 defines neuroendocrine differentiation of lung tumors.

Ito T, Matsubara D, Tanaka I, Makiya K, Tanei ZI, Kumagai Y, Shiu SJ, Nakaoka HJ, Ishikawa S, Isagawa T, Morikawa T, Shinozaki-Ushiku A, Goto Y, Nakano T, Tsuchiya T, Tsubochi H, Komura D, Aburatani H, Dobashi Y, Nakajima J, Endo S, Fukayama M, Sekido Y, Niki T, Murakami Y.

Cancer Sci. 2016 Oct;107(10):1527-1538. doi: 10.1111/cas.13013. Epub 2016 Sep 9.

15.

New metastatic model of human small-cell lung cancer by orthotopic transplantation in mice.

Sakamoto S, Inoue H, Ohba S, Kohda Y, Usami I, Masuda T, Kawada M, Nomoto A.

Cancer Sci. 2015 Apr;106(4):367-74. doi: 10.1111/cas.12624. Epub 2015 Feb 26.

16.

Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer.

Polański R, Hodgkinson CL, Fusi A, Nonaka D, Priest L, Kelly P, Trapani F, Bishop PW, White A, Critchlow SE, Smith PD, Blackhall F, Dive C, Morrow CJ.

Clin Cancer Res. 2014 Feb 15;20(4):926-37. doi: 10.1158/1078-0432.CCR-13-2270. Epub 2013 Nov 25.

17.

CXCR4 chemokine receptor antagonists: perspectives in SCLC.

Burger JA, Stewart DJ.

Expert Opin Investig Drugs. 2009 Apr;18(4):481-90. doi: 10.1517/13543780902804249 . Review.

PMID:
19335276
18.

PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.

Zandi R, Selivanova G, Christensen CL, Gerds TA, Willumsen BM, Poulsen HS.

Clin Cancer Res. 2011 May 1;17(9):2830-41. doi: 10.1158/1078-0432.CCR-10-3168. Epub 2011 Mar 17.

19.

Expression of the coxsackie adenovirus receptor in neuroendocrine lung cancers and its implications for oncolytic adenoviral infection.

Wunder T, Schmid K, Wicklein D, Groitl P, Dobner T, Lange T, Anders M, Schumacher U.

Cancer Gene Ther. 2013 Jan;20(1):25-32. doi: 10.1038/cgt.2012.80. Epub 2012 Nov 30.

PMID:
23196273
20.

Supplemental Content

Support Center